Invitrogen™ ELISA kit of VEGF-A porcine

Ref.: BL-RE-106402Manufacturer ref.: ES25RBX10 10 x 96 tests
Price on request
Custom pricing depending on configuration and quantity.

VEGF is a homodimer glycoprotein with 45 kDa disulfide bridges involved in angiogenesis, which promotes tumour progression and metastases. VEGF has a variety of effects on vascular endothelium, including the ability to promote vascular endothelium.

Accession number
P49151
Dose range
40 to 10.000 pg/ml
Sensitivity of the dosage
40 pg/ml
Conjugate
Biotin
Product type
ELISA
Brand
Invitrogen

VEGF is a homodimer glycoprotein with 45 kDa disulfide bridges involved in angiogenesis, which promotes tumour progression and metastases. VEGF has a variety of effects on vascular endothelium, including the ability to promote vascular endothelium.

VEGF is a homodimer glycoprotein with 45 kDa disulfide bridges involved in angiogenesis, which promotes tumour progression and metastases. VEGF has various effects on vascular endothelium, including the ability to promote endothelial cell viability, mitogenesis, chemotaxia and vascular permeability. VEGF's family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and PIGF. The VEGF and its receptor system have proven to be the fundamental regulators of cell signaling of langenogenicity. Most tumours have the absolute requirement of angiogenesis and VEGF has been described as the most potent angiogenic cytokine associated with this process. To date, 5 different VEGF isoforms have been described. These isoforms are generated following an alternative splicing from a single VEGF gene. These various isoforms have been shown to bind to two tyrosine kinase flt-1 receptors (VEGFR-1) and flk-1/KDR (VEGFR-2 receptors), which have been expressed almost exclusively on endothelial cells. VEGF and its high affinity binding receptors, tyrosines kinases FLK1 and FLT1, are considered important for the development of embryonic vasculature. Studies have shown that an alternately spliced form of FLT1 produces a soluble protein, called sFLT1, which binds vascular endothelial growth factor with high affinity, acting as an inhibitor in angiogenesis. High levels of VEGF are associated with POEMS syndrome, also known as Crow-Fukase syndrome, which affects several organs of the body.

Sensitivity

Sensitivity of the dosage: 40 pg/ml.

Measurement range

Dosing range: 40 to 10,000 pg/ml.

Duration of dosing

Total duration of dosing: 4 h 45 min.

Reproducibility

Coefficient of intradose variation < 10%, interdose < 12%.

Samples

Sample type: Plasma, Serum, Surnatant (plasma volume, 50 μl) Supernatant, 50 μl)

Technical specifications

General
BrandInvitrogen
Supplier ref. (Fisher Scientific)17718273
Specifications
Accession numberP49151
Dose range40 to 10.000 pg/ml
Sensitivity of the dosage40 pg/ml
ConjugateBiotin
Product typeELISA
Type of samplePlasma, Serum, Surnatant
For use with (equipment)Colorimetric microplate reader
Genetic identification (Enter)397157
Gene symbol(s)VEGFA analysis
Coefficient of inter-dose variation< 12%
Coefficient of intra-dose variation< 10%
Contents of kits96-well pre-coated sheetings, etc., at the same time as the pre-casting plate, at the same time as the pre-casting plate.
Marker or dyeHRP
Quantity10 x 96 tests
Regulatory statusRUO
TargetVEGF analysis
Test time1 h 20 min
Physical characteristics
Volume of samplePlasma, 50 μl-Surnatant, 50 μl-Serum, 50 μl
Storage and shipping
Storage conditions2°C to 8°C
Total duration of dosing4 h 45 min

Origin and customs

Manufacturer ref.ES25RBX10
Country of originUnited States
HS customs code3002 12 00 00
A question or a specific configuration?
Contact us for a quote.